Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2017 Apr;8(2):377-384.
doi: 10.1007/s13300-017-0234-y. Epub 2017 Feb 20.

Glycemic Control in a Real-Life Setting in Patients With Type 2 Diabetes Treated With IDegLira at a Single Swiss Center

Affiliations
Free PMC article

Glycemic Control in a Real-Life Setting in Patients With Type 2 Diabetes Treated With IDegLira at a Single Swiss Center

Daniela Sofra. Diabetes Ther. .
Free PMC article

Abstract

Introduction: The aim of the present study was to describe clinical outcomes in a real-world population of Swiss patients with long-standing, poorly controlled type 2 diabetes after switching to IDegLira [a combination of insulin degludec (IDeg) and liraglutide (Lira)].

Methods: This was a prospective, open-label, single-center observational follow-up at the Cabinet Medical de Diabétologie, Lausanne, Switzerland, of 61 patients [HbA1c 9.2% (77 mmol/mol) and 56.1 U total insulin] initiated with IDegLira at 20 dose steps (20 U IDeg/0.72 mg Lira), except in insulin-naïve patients who began treatment at 16 dose steps. Thereafter, the dose was titrated by four dose steps once weekly, according to individualized fasting blood glucose targets. Information about glycemic control, total insulin dose, weight, and blood pressure, along with any adverse events, was collected from medical records and patient reports during clinic visits at baseline, 3 months, and end of follow-up.

Results: Over 6 months of follow-up, mean HbA1c improved (decrease of 1.7%) to 7.5% with concomitant weight loss. Switching to IDegLira resulted in a lower (-14.6 U) total insulin dose compared with baseline for those patients previously on insulin. There were no episodes of severe hypoglycemia during treatment with IDegLira. There were small decreases in both mean systolic and mean diastolic blood pressure with IDegLira. Six patients discontinued treatment early because of adverse gastrointestinal events with IDegLira.

Conclusion: Switching to IDegLira, mostly from regimens using insulin in conjunction with oral antidiabetic medications in a real-world population of patients with type 2 diabetes, resulted in improved glucose control with a lower insulin dose and weight loss.

Keywords: IDegLira; Incretin; Insulin; Observational study; Type 2 diabetes.

Figures

Fig. 1
Fig. 1
Glucose control (a), body weight (b), insulin dose (c), and blood pressure (d) before and after switching to IDegLira in 55 Swiss patients who completed follow-up. Red dotted line in a shows normal value for HbA1c (5.5%). HbA 1c glycated hemoglobin, IDegLira insulin degludec/liraglutide, Δ mean change from baseline

Similar articles

See all similar articles

Cited by 9 articles

See all "Cited by" articles

References

    1. Madsbad S, Kielgast U, Asmar M, Deacon CF, Torekov SS, Holst JJ. An overview of once-weekly glucagon-like peptide-1 receptor agonists–available efficacy and safety data and perspectives for the future. Diabetes Obes Metab. 2011;13:394–407. doi: 10.1111/j.1463-1326.2011.01357.x. - DOI - PubMed
    1. Karagiannis T, Liakos A, Bekiari E, et al. Efficacy and safety of once-weekly glucagon-like peptide 1 receptor agonists for the management of type 2 diabetes: a systematic review and meta-analysis of randomized controlled trials. Diabetes Obes Metab. 2015;17:1065–1074. doi: 10.1111/dom.12541. - DOI - PubMed
    1. Heise T, Nosek L, Bøttcher SG, Hastrup H, Haahr H. Ultra-long-acting insulin degludec has a flat and stable glucose-lowering effect in type 2 diabetes. Diabetes Obes Metab. 2012;14:944–950. doi: 10.1111/j.1463-1326.2012.01638.x. - DOI - PubMed
    1. Haahr H, Heise T. A review of the pharmacological properties of insulin degludec and their clinical relevance. Clin Pharmacokinet. 2014;53:787–800. doi: 10.1007/s40262-014-0165-y. - DOI - PMC - PubMed
    1. Einhorn D, Handelsman Y, Bode BW, Endahl LA, Mersebach H, King AB. Patients achieving good glycemic control (HbA1c <7.0%) experience a lower rate of hypoglycemia with insulin degludec than with insulin glargine: a meta-analysis of phase 3A trials. Endocr Pract. 2015;21:917–926. doi: 10.4158/EP14523.OR. - DOI - PubMed

LinkOut - more resources

Feedback